Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
:RPRX
RPRX Stock Chart & Stats
$38.53
$0.10(0.38%)
At close: 4:00 PM EST
$38.53
$0.10(0.38%)
Day’s Range― - ―
52-Week Range$24.05 - $41.24
Previous CloseN/A
Volume726.99K
Average Volume (3M)4.61M
Market Cap
$22.16B
Enterprise Value$30.96B
Total Cash (Recent Filing)$955.04M
Total Debt (Recent Filing)$8.97B
Price to Earnings (P/E)22.0
Beta0.18
Next Earnings
Feb 17, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend Yield2.28%
Share Statistics
EPS (TTM)1.17
Shares Outstanding427,247,500
10 Day Avg. Volume4,980,310
30 Day Avg. Volume4,612,175
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)1.64
Price to Sales (P/S)5.03
P/FCF Ratio4.11
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue13.17
Enterprise Value/Gross Profit13.17
Enterprise Value/Ebitda19.55
Forecast
1Y Price Target
$44.00Price Target Upside14.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.56
Revenue Forecast (FY)$2.99B
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAll key metrics have outperformed and the company is on track to meet or exceed its $4.7B 2030 revenue target.
Portfolio ExpansionRPRX is in the early stages of a multi-year portfolio expansion that is underappreciated in the context of a large, growing market for royalty funding, with additional potential tailwinds from China biotech innovation trends.
Price Target IncreaseThe price target for Royalty Pharma PLC has been increased from $42.00 to $45.00.
Bears Say
Investor QuestionsRPRX has identified frequently asked questions among investors that have kept some on the sidelines.
Royalty Revenue ConcernsRecent concerns around downside to the key royalty revenue stream from VRTX are now reflected in both the stock and the company’s forward guidance, derisking financials to some extent.
Royalty Pharma News
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $24.05 and its highest was $41.24 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Royalty Pharma PLC’s market cap is $22.16B.
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Feb 17, 2026 which is in 62 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Nov 05, 2025. The company reported $1.173 earnings per share for the quarter, beating the consensus estimate of $0.994 by $0.179.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 2.28%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is 1.27.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 427,247,500 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.173 in its last earnings report, beating expectations of $0.994. Following the earnings report the stock price went up 6.83%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Currently, no hedge funds are holding shares in RPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (14.20% Upside)
$44.00 (14.20% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.4%
Last 30 Days ▲ 18.4%
Last 30 Days ▲ 18.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.02%
12-Months-Change
Fundamentals
Return on Equity
11.51%
Trailing 12-Months
Asset Growth
7.23%
Trailing 12-Months
Company Description
Royalty Pharma PLC
Royalty Pharma (RPRX) is a leading investment firm focused on acquiring and managing revenue-producing intellectual property in the biopharmaceutical sector. The company specializes in purchasing royalty interests from pharmaceutical and biotechnology companies, which allows them to receive a share of the revenue generated from marketed drugs. Royalty Pharma operates primarily within the healthcare sector, providing capital to innovators while offering investors exposure to the growing biopharma market through a diversified portfolio of royalties linked to high-value therapies.
RPRX Company Deck
RPRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Royalty Pharma reported a strong financial performance with significant growth and strategic acquisitions in the third quarter of 2025, leading to an upward revision of its full-year guidance. Despite challenges such as the upcoming decline in Promacta royalties and increased interest expenses, the company's diversified portfolio and pipeline expansion underline its growth potential.View all RPRX earnings summariesRPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
RPRX Stock 12 Month Forecast
Average Price Target
$44.00
▲(14.20% Upside)
Technical Analysis
Ownership Overview
1.80% Insiders
18.51% Mutual Funds
27.49% Other Institutional Investors
41.25% Public Companies and
Individual Investors